Elan Issues Response to Royalty Pharma Bid, Tells Holders to Take No Action
The Board of Elan Corporation, plc (NYSE: ELN) (Elan) notes today's announcement regarding the revised offer by Echo Pharma Acquisition Limited (“Royalty Pharma”) to acquire Elan's shares under Rule 2.5 of the Irish Takeover Rules.
The Board of Elan will, as before, in line with its obligations under Irish Takeover law, assess the Royalty Pharma announcement and will advise its shareholders accordingly. In the meantime, Elan shareholders are strongly advised to take no action in relation to the Royalty Pharma offer.
The Directors of Elan accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.
Any holder of 1% or more of any class of relevant securities of Elan or of Royalty Pharma may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2007 (as amended).
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.